Feb 21, 2019 - It is a statistical fact that investors overweight their home country. For U.S. citizens, this is least detrimental since it's the highest weighted (~39%) globally. It is still inefficient, however.Wh
Feb 19, 2019 - The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
Feb 19, 2019 - Since the acquisition of Actavis, Teva's balance sheet and cash flow were destroyed. It now has focused relentlessly on realigning its strategy and restoring the balance sheet.Halfway through now, it
Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
Feb 13, 2019 - Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
Feb 13, 2019 - Top Research Reports for ExxonMobil, Merck & Danaher
Feb 11, 2019 - AbbVie missed its Q4 earnings expectations, but it does have many other products to help it get back on track in the coming quarters.The big loss for the quarter was due to international sales of Humi
Feb 11, 2019 - Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Feb 08, 2019 - Lilly's earnings fall in line with expectations, modest revenue beat from higher than anticipated performance in Mature Brands.Verzenio sales were much lower than expectations, reflecting competitive